Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lung Neoplasms 14Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Urinary Bladder Neoplasms 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Renal Cell 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2

Interventions

Specimen Handling 5Magnetic Resonance Spectroscopy 5Cisplatin 4trastuzumab deruxtecan 3Platinum 3Docetaxel 3Carboplatin 3Biopsy 3pembrolizumab 2entrectinib 2darolutamide 2Trastuzumab 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Goserelin 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1sacituzumab govitecan 1pyrotinib 1pertuzumab 1luprolide acetate gel depot 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1camrelizumab 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Disulfides × 90 days × Clear all
NCT00588770 2026-05-29

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
403 enrolled 10 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡